Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. https://doi.org/10.3322/caac.21590.

Article  PubMed  Google Scholar 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492.

Article  PubMed  Google Scholar 

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–53. https://doi.org/10.1002/ijc.31937.

Article  CAS  PubMed  Google Scholar 

Cervenka BP, Rao S, Bewley AF. Head and neck cancer and the elderly patient. Otolaryngol Clin North Am. 2018;51:741–51. https://doi.org/10.1016/j.otc.2018.03.004.

Article  PubMed  Google Scholar 

Johnson DE, Burtness B, Leemans CR, Lui V, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92. https://doi.org/10.1038/s41572-020-00224-3.

Article  PubMed  PubMed Central  Google Scholar 

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. https://doi.org/10.3322/caac.21442.

Article  PubMed  Google Scholar 

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–28. https://doi.org/10.1016/S0140-6736(19)32591-7.

Article  CAS  PubMed  Google Scholar 

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67. https://doi.org/10.1056/NEJMoa1602252.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, et al. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018;3: e98811. https://doi.org/10.1172/jci.insight.98811.

Article  PubMed  PubMed Central  Google Scholar 

Liu X, Nie L, Zhang Y, Yan Y, Wang C, Colic M, Olszewski K, Horbath A, Chen X, Lei G, Mao C, Wu S, Zhuang L, Poyurovsky MV, James You M, Hart T, Billadeau DD, Chen J, Gan B. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat Cell Biol. 2023;25:404–14. https://doi.org/10.1038/s41556-023-01091-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng P, Zhou C, Ding Y, Duan S. Disulfidptosis: a new target for metabolic cancer therapy. J Exp Clin Cancer Res. 2023;42:103. https://doi.org/10.1186/s13046-023-02675-4.

Article  PubMed  PubMed Central  Google Scholar 

Zheng T, Liu Q, Xing F, Zeng C, Wang W. Disulfidptosis: a new form of programmed cell death. J Exp Clin Cancer Res. 2023;42:137. https://doi.org/10.1186/s13046-023-02712-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Yang W, Li Y, Ma L, Ji Z. Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients. Front Immunol. 2023;14:1198878. https://doi.org/10.3389/fimmu.2023.1198878.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Xue W, Zhang Y, Gao Y, Wang Y. A novel disulfidptosis-related immune checkpoint genes signature: forecasting the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2023. https://doi.org/10.1007/s00432-023-05076-4.

Article  PubMed  PubMed Central  Google Scholar 

Feng Z, Zhao Q, Ding Y, Xu Y, Sun X, Chen Q, Zhang Y, Miao J, Zhu J. Identification a unique disulfidptosis classification regarding prognosis and immune landscapes in thyroid carcinoma and providing therapeutic strategies. J Cancer Res Clin Oncol. 2023. https://doi.org/10.1007/s00432-023-05006-4.

Article  PubMed  PubMed Central  Google Scholar 

Ghaforui-Fard S, Vafaee R, Taheri M. Taurine-upregulated gene 1: a functional long noncoding RNA in tumorigenesis. J Cell Physiol. 2019;234:17100–12. https://doi.org/10.1002/jcp.28464.

Article  CAS  PubMed  Google Scholar 

Xu C, Han P, Ren W, Dai H, Bai Y, Shen Z, Li B, Shao Y. The genetic polymorphisms in the MIR17HG gene are associated with the risk of head and neck squamous cell carcinoma in the chinese han population. Biomed Res Int. 2020;2020:2329196. https://doi.org/10.1155/2020/2329196.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang S, Chen X, Qiao T. Long non-coding RNA MIR4435-2HG promotes the progression of head and neck squamous cell carcinoma by regulating the miR-383-5p/RBM3 axis. Oncol Rep. 2021;45:99. https://doi.org/10.3892/or.2021.8050.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao W, Liu JN, Liu Z, Wang X, Han ZG, Ji T, Chen WT, Zou X. A three-lncRNA signature derived from the Atlas of ncRNA in cancer (TANRIC) database predicts the survival of patients with head and neck squamous cell carcinoma. Oral Oncol. 2017;65:94–101. https://doi.org/10.1016/j.oraloncology.2016.12.017.

Article  CAS  PubMed  Google Scholar 

Duan Y, Yue K, Ye B, Chen P, Zhang J, He Q, Wu Y, Lai Q, Li H, Wu Y, Jing C, Wang X. LncRNA MALAT1 promotes growth and metastasis of head and neck squamous cell carcinoma by repressing VHL through a non-canonical function of EZH2. Cell Death Dis. 2023;14:149. https://doi.org/10.1038/s41419-023-05667-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576–82. https://doi.org/10.1038/nature14129.

Zhang D, Zhang X, Liu Z, Han T, Zhao K, Xu X, Zhang X, Ren X, Qin C. An integrative multi-omics analysis based on disulfidptosis-related prognostic signature and distinct subtypes of clear cell renal cell carcinoma. Front Oncol. 2023;13:1207068. https://doi.org/10.3389/fonc.2023.1207068.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang C, Mei H, Peng L, Jiang F, Xie B, Li J. Prognostic correlation of an autophagy-related gene signature in patients with head and neck squamous cell carcinoma. Comput Math Methods Med. 2020;2020:7397132. https://doi.org/10.1155/2020/7397132.

Article  PubMed  PubMed Central  Google Scholar 

Feng C, Liu S, Shang Z. Identification and validation of an EMT-related LncRNA signature for HNSCC to predict survival and immune landscapes. Front Cell Dev Biol. 2021;9:798898. https://doi.org/10.3389/fcell.2021.798898.

Article  PubMed  Google Scholar 

Zhao H, Wang F, Wang X, Zhao X, Ji J. HPV-related prognostic signature predicts survival in head and neck squamous cell carcinoma. J Oncol. 2022;2022:7357566. https://doi.org/10.1155/2022/7357566.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang X, Ke J, Jia L, An X, Ma H, Li Z, Yuan W. A novel cuproptosis-related gene signature of prognosis and immune microenvironment in head and neck squamous cell carcinoma cancer. J Cancer Res Clin Oncol. 2023;149:203–18. https://doi.org/10.1007/s00432-022-04471-7.

Article  CAS  PubMed  Google Scholar 

McDermott JD, Bowles DW. Epidemiology of head and neck squamous cell carcinomas: impact on staging and prevention strategies. Curr Treat Options Oncol. 2019;20:43. https://doi.org/10.1007/s11864-019-0650-5.

Article  PubMed  Google Scholar 

Ebrahimi A, Luk PP, Low H, McDowell L, Magarey M, Smith PN, Perriman DM, Veness M, Gupta R, Clark JR. A critical analysis of the 8th edition TNM staging for head and neck cutaneous squamous cell carcinoma with lymph node metastases and comparison to N1S3 stage and ITEM risk score: a multicenter study. J Surg Oncol. 2021;123:1531–9. https://doi.org/10.1002/jso.26410.

Article  PubMed  Google Scholar 

Liao Y, Li P, Wang Y, Chen H, Ning S, Su D. Construction of asthma related competing endogenous RNA network revealed novel long non-coding RNAs and potential new drugs. Respir Res. 2020;21:14. https://doi.org/10.1186/s12931-019-1257-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhuang Q, Jin Z, Zheng X, Jin T, Xiang L. Long non-coding RNA LINC00460 serves as a potential biomarker and oncogene via regulation of the miR-320b/PBX3 axis in acute myeloid leukemia. Mol Med Rep. 2021;23:435. https://doi.org/10.3892/mmr.2021.12074.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598–608. https://doi.org/10.1158/1535-7163.MCT-17-0386.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang H, Yu M, Zhong S, You Y, Feng F. Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer. J Ovarian Res. 2022;15:18. https://doi.org/10.1186/s13048-022-00955-9.

Article  CAS  PubMed  PubMed Central